Logo image of EUDA

EUDA HEALTH HOLDINGS LTD (EUDA) Stock Fundamental Analysis

NASDAQ:EUDA - Nasdaq - VGG3142E1051 - Common Stock - Currency: USD

3.44  +0.09 (+2.69%)

After market: 3.57 +0.13 (+3.78%)

Fundamental Rating

1

Taking everything into account, EUDA scores 1 out of 10 in our fundamental rating. EUDA was compared to 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of EUDA have multiple concerns. EUDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EUDA has reported negative net income.
EUDA had a negative operating cash flow in the past year.
EUDA Yearly Net Income VS EBIT VS OCF VS FCFEUDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of EUDA (-495.07%) is worse than 98.04% of its industry peers.
Industry RankSector Rank
ROA -495.07%
ROE N/A
ROIC N/A
ROA(3y)-256.81%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EUDA Yearly ROA, ROE, ROICEUDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

EUDA has a Gross Margin (22.72%) which is in line with its industry peers.
EUDA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EUDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.67%
GM growth 5YN/A
EUDA Yearly Profit, Operating, Gross MarginsEUDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200

More info and screens

0

2. Health

2.1 Basic Checks

EUDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
EUDA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, EUDA has a worse debt to assets ratio.
EUDA Yearly Shares OutstandingEUDA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
EUDA Yearly Total Debt VS Total AssetsEUDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

EUDA has an Altman-Z score of -34.74. This is a bad value and indicates that EUDA is not financially healthy and even has some risk of bankruptcy.
EUDA has a worse Altman-Z score (-34.74) than 93.14% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -34.74
ROIC/WACCN/A
WACC9.07%
EUDA Yearly LT Debt VS Equity VS FCFEUDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M 40M 60M 80M

2.3 Liquidity

EUDA has a Current Ratio of 0.13. This is a bad value and indicates that EUDA is not financially healthy enough and could expect problems in meeting its short term obligations.
EUDA has a worse Current ratio (0.13) than 94.12% of its industry peers.
A Quick Ratio of 0.13 indicates that EUDA may have some problems paying its short term obligations.
The Quick ratio of EUDA (0.13) is worse than 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
EUDA Yearly Current Assets VS Current LiabilitesEUDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for EUDA have decreased strongly by -104.76% in the last year.
Measured over the past years, EUDA shows a very negative growth in Revenue. The Revenue has been decreasing by -25.25% on average per year.
EPS 1Y (TTM)-104.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.04%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-25.25%
Revenue growth 5YN/A
Sales Q2Q%1729.43%

3.2 Future

EUDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.71% yearly.
The Revenue is expected to grow by 128.76% on average over the next years. This is a very strong growth
EPS Next Y21.72%
EPS Next 2Y31.87%
EPS Next 3Y31.71%
EPS Next 5YN/A
Revenue Next Year66.63%
Revenue Next 2Y83.8%
Revenue Next 3Y128.76%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EUDA Yearly Revenue VS EstimatesEUDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 10M 20M 30M 40M
EUDA Yearly EPS VS EstimatesEUDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 0.1 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EUDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EUDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EUDA Price Earnings VS Forward Price EarningsEUDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EUDA Per share dataEUDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

EUDA's earnings are expected to grow with 31.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.87%
EPS Next 3Y31.71%

More info and screens

0

5. Dividend

5.1 Amount

EUDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUDA HEALTH HOLDINGS LTD

NASDAQ:EUDA (6/6/2025, 8:00:02 PM)

After market: 3.57 +0.13 (+3.78%)

3.44

+0.09 (+2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)06-14 2024-06-14
Earnings (Next)N/A N/A
Inst Owners2.49%
Inst Owner Change-4.54%
Ins Owners15.51%
Ins Owner Change0%
Market Cap127.83M
Analysts82.86
Price Target6.12 (77.91%)
Short Float %0.11%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-312.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.1
BVpS-0.16
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -495.07%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.72%
FCFM N/A
ROA(3y)-256.81%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.67%
GM growth 5YN/A
F-Score4
Asset Turnover1.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.98%
Cap/Sales 0.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -34.74
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)4.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.04%
EPS Next Y21.72%
EPS Next 2Y31.87%
EPS Next 3Y31.71%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-25.25%
Revenue growth 5YN/A
Sales Q2Q%1729.43%
Revenue Next Year66.63%
Revenue Next 2Y83.8%
Revenue Next 3Y128.76%
Revenue Next 5YN/A
EBIT growth 1Y-99.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-188.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-188.9%
OCF growth 3YN/A
OCF growth 5YN/A